nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Mitomycin—urinary bladder cancer	0.108	0.506	CbGbCtD
Carfilzomib—ABCB1—Gemcitabine—urinary bladder cancer	0.0312	0.146	CbGbCtD
Carfilzomib—ABCB1—Cisplatin—urinary bladder cancer	0.0227	0.106	CbGbCtD
Carfilzomib—ABCB1—Etoposide—urinary bladder cancer	0.0223	0.104	CbGbCtD
Carfilzomib—ABCB1—Doxorubicin—urinary bladder cancer	0.0152	0.0709	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—urinary bladder cancer	0.0147	0.0686	CbGbCtD
Carfilzomib—PSMB10—prostate gland—urinary bladder cancer	0.0146	0.0842	CbGeAlD
Carfilzomib—PSMB8—prostate gland—urinary bladder cancer	0.00941	0.0543	CbGeAlD
Carfilzomib—PSMB5—prostate gland—urinary bladder cancer	0.00831	0.0479	CbGeAlD
Carfilzomib—PSMB10—female reproductive system—urinary bladder cancer	0.00797	0.046	CbGeAlD
Carfilzomib—PSMB8—seminal vesicle—urinary bladder cancer	0.00796	0.0459	CbGeAlD
Carfilzomib—PSMB1—prostate gland—urinary bladder cancer	0.00726	0.0419	CbGeAlD
Carfilzomib—PSMB2—prostate gland—urinary bladder cancer	0.00709	0.0409	CbGeAlD
Carfilzomib—PSMB5—seminal vesicle—urinary bladder cancer	0.00703	0.0405	CbGeAlD
Carfilzomib—PSMB8—urethra—urinary bladder cancer	0.0063	0.0363	CbGeAlD
Carfilzomib—PSMB1—seminal vesicle—urinary bladder cancer	0.00614	0.0354	CbGeAlD
Carfilzomib—PSMB2—seminal vesicle—urinary bladder cancer	0.00599	0.0346	CbGeAlD
Carfilzomib—PSMB5—smooth muscle tissue—urinary bladder cancer	0.00588	0.0339	CbGeAlD
Carfilzomib—PSMB5—urethra—urinary bladder cancer	0.00556	0.0321	CbGeAlD
Carfilzomib—PSMB1—smooth muscle tissue—urinary bladder cancer	0.00514	0.0297	CbGeAlD
Carfilzomib—PSMB2—smooth muscle tissue—urinary bladder cancer	0.00502	0.0289	CbGeAlD
Carfilzomib—PSMB1—renal system—urinary bladder cancer	0.00495	0.0286	CbGeAlD
Carfilzomib—PSMB1—urethra—urinary bladder cancer	0.00486	0.0281	CbGeAlD
Carfilzomib—PSMB2—renal system—urinary bladder cancer	0.00483	0.0279	CbGeAlD
Carfilzomib—PSMB2—urethra—urinary bladder cancer	0.00474	0.0274	CbGeAlD
Carfilzomib—PSMB10—lymph node—urinary bladder cancer	0.00466	0.0269	CbGeAlD
Carfilzomib—PSMB8—vagina—urinary bladder cancer	0.00464	0.0268	CbGeAlD
Carfilzomib—PSMB5—vagina—urinary bladder cancer	0.0041	0.0237	CbGeAlD
Carfilzomib—PSMB1—female reproductive system—urinary bladder cancer	0.00396	0.0229	CbGeAlD
Carfilzomib—PSMB2—female reproductive system—urinary bladder cancer	0.00387	0.0223	CbGeAlD
Carfilzomib—PSMB2—Azacitidine—Gemcitabine—urinary bladder cancer	0.00368	0.53	CbGdCrCtD
Carfilzomib—PSMB1—vagina—urinary bladder cancer	0.00359	0.0207	CbGeAlD
Carfilzomib—PSMB2—vagina—urinary bladder cancer	0.0035	0.0202	CbGeAlD
Carfilzomib—PSMB8—Podofilox—Etoposide—urinary bladder cancer	0.00327	0.471	CbGdCrCtD
Carfilzomib—PSMB8—lymph node—urinary bladder cancer	0.003	0.0173	CbGeAlD
Carfilzomib—PSMB5—lymph node—urinary bladder cancer	0.00265	0.0153	CbGeAlD
Carfilzomib—PSMB1—lymph node—urinary bladder cancer	0.00232	0.0134	CbGeAlD
Carfilzomib—PSMB2—lymph node—urinary bladder cancer	0.00226	0.0131	CbGeAlD
Carfilzomib—ABCB1—prostate gland—urinary bladder cancer	0.00108	0.00625	CbGeAlD
Carfilzomib—ABCB1—seminal vesicle—urinary bladder cancer	0.000916	0.00528	CbGeAlD
Carfilzomib—Aspartate aminotransferase increased—Cisplatin—urinary bladder cancer	0.000837	0.00352	CcSEcCtD
Carfilzomib—Asthenia—Mitomycin—urinary bladder cancer	0.000831	0.00349	CcSEcCtD
Carfilzomib—Neuritis—Doxorubicin—urinary bladder cancer	0.000815	0.00343	CcSEcCtD
Carfilzomib—Cardiac arrest—Etoposide—urinary bladder cancer	0.000809	0.0034	CcSEcCtD
Carfilzomib—Neutropenia—Gemcitabine—urinary bladder cancer	0.000806	0.00339	CcSEcCtD
Carfilzomib—ABCB1—epithelium—urinary bladder cancer	0.000796	0.00459	CbGeAlD
Carfilzomib—Diarrhoea—Mitomycin—urinary bladder cancer	0.000792	0.00333	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.000787	0.00331	CcSEcCtD
Carfilzomib—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.000777	0.00327	CcSEcCtD
Carfilzomib—Pneumonia—Gemcitabine—urinary bladder cancer	0.000773	0.00325	CcSEcCtD
Carfilzomib—Dizziness—Mitomycin—urinary bladder cancer	0.000766	0.00322	CcSEcCtD
Carfilzomib—Cardiac disorder—Thiotepa—urinary bladder cancer	0.000761	0.0032	CcSEcCtD
Carfilzomib—Pneumonia—Fluorouracil—urinary bladder cancer	0.00076	0.00319	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Gemcitabine—urinary bladder cancer	0.000757	0.00318	CcSEcCtD
Carfilzomib—Renal failure—Gemcitabine—urinary bladder cancer	0.000755	0.00318	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Gemcitabine—urinary bladder cancer	0.000753	0.00317	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Fluorouracil—urinary bladder cancer	0.000745	0.00313	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Fluorouracil—urinary bladder cancer	0.00074	0.00311	CcSEcCtD
Carfilzomib—ABCB1—renal system—urinary bladder cancer	0.000738	0.00426	CbGeAlD
Carfilzomib—Vomiting—Mitomycin—urinary bladder cancer	0.000736	0.0031	CcSEcCtD
Carfilzomib—Chills—Thiotepa—urinary bladder cancer	0.000736	0.00309	CcSEcCtD
Carfilzomib—Headache—Mitomycin—urinary bladder cancer	0.000726	0.00305	CcSEcCtD
Carfilzomib—ABCB1—urethra—urinary bladder cancer	0.000725	0.00418	CbGeAlD
Carfilzomib—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.000706	0.00297	CcSEcCtD
Carfilzomib—Renal failure—Cisplatin—urinary bladder cancer	0.000704	0.00296	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Cisplatin—urinary bladder cancer	0.000702	0.00295	CcSEcCtD
Carfilzomib—Back pain—Thiotepa—urinary bladder cancer	0.00069	0.0029	CcSEcCtD
Carfilzomib—Neutropenia—Etoposide—urinary bladder cancer	0.000688	0.00289	CcSEcCtD
Carfilzomib—Nausea—Mitomycin—urinary bladder cancer	0.000688	0.00289	CcSEcCtD
Carfilzomib—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.000679	0.00286	CcSEcCtD
Carfilzomib—Hypoaesthesia—Fluorouracil—urinary bladder cancer	0.000675	0.00284	CcSEcCtD
Carfilzomib—Pneumonia—Etoposide—urinary bladder cancer	0.00066	0.00277	CcSEcCtD
Carfilzomib—Anaemia—Thiotepa—urinary bladder cancer	0.00066	0.00277	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.000647	0.00272	CcSEcCtD
Carfilzomib—Renal failure—Etoposide—urinary bladder cancer	0.000645	0.00271	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Etoposide—urinary bladder cancer	0.000643	0.0027	CcSEcCtD
Carfilzomib—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.00064	0.00269	CcSEcCtD
Carfilzomib—Leukopenia—Thiotepa—urinary bladder cancer	0.000639	0.00269	CcSEcCtD
Carfilzomib—Cough—Thiotepa—urinary bladder cancer	0.000623	0.00262	CcSEcCtD
Carfilzomib—Chills—Gemcitabine—urinary bladder cancer	0.000619	0.0026	CcSEcCtD
Carfilzomib—Hypertension—Thiotepa—urinary bladder cancer	0.000616	0.00259	CcSEcCtD
Carfilzomib—Sepsis—Methotrexate—urinary bladder cancer	0.00061	0.00256	CcSEcCtD
Carfilzomib—Arthralgia—Thiotepa—urinary bladder cancer	0.000608	0.00255	CcSEcCtD
Carfilzomib—Cardiac disorder—Cisplatin—urinary bladder cancer	0.000597	0.00251	CcSEcCtD
Carfilzomib—ABCB1—female reproductive system—urinary bladder cancer	0.000591	0.00341	CbGeAlD
Carfilzomib—Hypoaesthesia—Etoposide—urinary bladder cancer	0.000586	0.00246	CcSEcCtD
Carfilzomib—Back pain—Gemcitabine—urinary bladder cancer	0.000581	0.00244	CcSEcCtD
Carfilzomib—Infection—Thiotepa—urinary bladder cancer	0.000579	0.00243	CcSEcCtD
Carfilzomib—Sepsis—Epirubicin—urinary bladder cancer	0.00057	0.0024	CcSEcCtD
Carfilzomib—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00057	0.0024	CcSEcCtD
Carfilzomib—Hepatic failure—Methotrexate—urinary bladder cancer	0.000567	0.00239	CcSEcCtD
Carfilzomib—Anorexia—Thiotepa—urinary bladder cancer	0.000555	0.00233	CcSEcCtD
Carfilzomib—Anaemia—Gemcitabine—urinary bladder cancer	0.000555	0.00233	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—urinary bladder cancer	0.000552	0.00232	CcSEcCtD
Carfilzomib—Cardiac disorder—Etoposide—urinary bladder cancer	0.000547	0.0023	CcSEcCtD
Carfilzomib—Anaemia—Fluorouracil—urinary bladder cancer	0.000546	0.00229	CcSEcCtD
Carfilzomib—Muscle spasms—Cisplatin—urinary bladder cancer	0.000538	0.00226	CcSEcCtD
Carfilzomib—Leukopenia—Gemcitabine—urinary bladder cancer	0.000537	0.00226	CcSEcCtD
Carfilzomib—ABCB1—vagina—urinary bladder cancer	0.000534	0.00308	CbGeAlD
Carfilzomib—Hepatic failure—Epirubicin—urinary bladder cancer	0.000531	0.00223	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000531	0.00223	CcSEcCtD
Carfilzomib—Chills—Etoposide—urinary bladder cancer	0.000528	0.00222	CcSEcCtD
Carfilzomib—Leukopenia—Fluorouracil—urinary bladder cancer	0.000528	0.00222	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—urinary bladder cancer	0.000528	0.00222	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—urinary bladder cancer	0.000526	0.00221	CcSEcCtD
Carfilzomib—Cough—Gemcitabine—urinary bladder cancer	0.000524	0.0022	CcSEcCtD
Carfilzomib—Hypertension—Gemcitabine—urinary bladder cancer	0.000518	0.00218	CcSEcCtD
Carfilzomib—Anaemia—Cisplatin—urinary bladder cancer	0.000517	0.00217	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—urinary bladder cancer	0.000517	0.00217	CcSEcCtD
Carfilzomib—Arthralgia—Gemcitabine—urinary bladder cancer	0.000511	0.00215	CcSEcCtD
Carfilzomib—Decreased appetite—Thiotepa—urinary bladder cancer	0.000506	0.00213	CcSEcCtD
Carfilzomib—Fatigue—Thiotepa—urinary bladder cancer	0.000502	0.00211	CcSEcCtD
Carfilzomib—Leukopenia—Cisplatin—urinary bladder cancer	0.000501	0.00211	CcSEcCtD
Carfilzomib—Pain—Thiotepa—urinary bladder cancer	0.000498	0.00209	CcSEcCtD
Carfilzomib—Constipation—Thiotepa—urinary bladder cancer	0.000498	0.00209	CcSEcCtD
Carfilzomib—Back pain—Etoposide—urinary bladder cancer	0.000496	0.00209	CcSEcCtD
Carfilzomib—Muscle spasms—Etoposide—urinary bladder cancer	0.000493	0.00207	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—urinary bladder cancer	0.000491	0.00207	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.000487	0.00205	CcSEcCtD
Carfilzomib—Infection—Gemcitabine—urinary bladder cancer	0.000487	0.00205	CcSEcCtD
Carfilzomib—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00048	0.00202	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—urinary bladder cancer	0.000479	0.00201	CcSEcCtD
Carfilzomib—Infection—Fluorouracil—urinary bladder cancer	0.000479	0.00201	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—urinary bladder cancer	0.000478	0.00201	CcSEcCtD
Carfilzomib—Pain in extremity—Epirubicin—urinary bladder cancer	0.000477	0.00201	CcSEcCtD
Carfilzomib—Anaemia—Etoposide—urinary bladder cancer	0.000474	0.00199	CcSEcCtD
Carfilzomib—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000472	0.00198	CcSEcCtD
Carfilzomib—Anorexia—Gemcitabine—urinary bladder cancer	0.000467	0.00196	CcSEcCtD
Carfilzomib—Body temperature increased—Thiotepa—urinary bladder cancer	0.00046	0.00194	CcSEcCtD
Carfilzomib—Anorexia—Fluorouracil—urinary bladder cancer	0.000459	0.00193	CcSEcCtD
Carfilzomib—Leukopenia—Etoposide—urinary bladder cancer	0.000459	0.00193	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000454	0.00191	CcSEcCtD
Carfilzomib—Infection—Cisplatin—urinary bladder cancer	0.000454	0.00191	CcSEcCtD
Carfilzomib—Cough—Etoposide—urinary bladder cancer	0.000447	0.00188	CcSEcCtD
Carfilzomib—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000447	0.00188	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000447	0.00188	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000446	0.00188	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.000443	0.00186	CcSEcCtD
Carfilzomib—Insomnia—Gemcitabine—urinary bladder cancer	0.000443	0.00186	CcSEcCtD
Carfilzomib—Hypertension—Etoposide—urinary bladder cancer	0.000443	0.00186	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000442	0.00186	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000439	0.00185	CcSEcCtD
Carfilzomib—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000437	0.00184	CcSEcCtD
Carfilzomib—Insomnia—Fluorouracil—urinary bladder cancer	0.000436	0.00183	CcSEcCtD
Carfilzomib—Anorexia—Cisplatin—urinary bladder cancer	0.000435	0.00183	CcSEcCtD
Carfilzomib—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000434	0.00183	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.00043	0.00181	CcSEcCtD
Carfilzomib—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000429	0.00181	CcSEcCtD
Carfilzomib—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000426	0.00179	CcSEcCtD
Carfilzomib—Fatigue—Gemcitabine—urinary bladder cancer	0.000422	0.00178	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.00042	0.00177	CcSEcCtD
Carfilzomib—Pain—Gemcitabine—urinary bladder cancer	0.000419	0.00176	CcSEcCtD
Carfilzomib—Constipation—Gemcitabine—urinary bladder cancer	0.000419	0.00176	CcSEcCtD
Carfilzomib—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000419	0.00176	CcSEcCtD
Carfilzomib—Asthenia—Thiotepa—urinary bladder cancer	0.000418	0.00176	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000416	0.00175	CcSEcCtD
Carfilzomib—Infection—Etoposide—urinary bladder cancer	0.000416	0.00175	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000414	0.00174	CcSEcCtD
Carfilzomib—Neutropenia—Methotrexate—urinary bladder cancer	0.000412	0.00173	CcSEcCtD
Carfilzomib—Pain—Fluorouracil—urinary bladder cancer	0.000412	0.00173	CcSEcCtD
Carfilzomib—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00041	0.00172	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.00041	0.00172	CcSEcCtD
Carfilzomib—Dyspnoea—Cisplatin—urinary bladder cancer	0.000407	0.00171	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000402	0.00169	CcSEcCtD
Carfilzomib—Anorexia—Etoposide—urinary bladder cancer	0.000399	0.00168	CcSEcCtD
Carfilzomib—Diarrhoea—Thiotepa—urinary bladder cancer	0.000399	0.00168	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000398	0.00167	CcSEcCtD
Carfilzomib—Decreased appetite—Cisplatin—urinary bladder cancer	0.000397	0.00167	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—urinary bladder cancer	0.000395	0.00166	CcSEcCtD
Carfilzomib—Pain—Cisplatin—urinary bladder cancer	0.000391	0.00164	CcSEcCtD
Carfilzomib—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000387	0.00163	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—urinary bladder cancer	0.000386	0.00162	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—urinary bladder cancer	0.000386	0.00162	CcSEcCtD
Carfilzomib—Dizziness—Thiotepa—urinary bladder cancer	0.000385	0.00162	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000383	0.00161	CcSEcCtD
Carfilzomib—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000381	0.0016	CcSEcCtD
Carfilzomib—Dyspnoea—Etoposide—urinary bladder cancer	0.000373	0.00157	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000372	0.00156	CcSEcCtD
Carfilzomib—Vomiting—Thiotepa—urinary bladder cancer	0.00037	0.00156	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—urinary bladder cancer	0.00037	0.00156	CcSEcCtD
Carfilzomib—Headache—Thiotepa—urinary bladder cancer	0.000365	0.00153	CcSEcCtD
Carfilzomib—Decreased appetite—Etoposide—urinary bladder cancer	0.000364	0.00153	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—urinary bladder cancer	0.000361	0.00152	CcSEcCtD
Carfilzomib—Body temperature increased—Cisplatin—urinary bladder cancer	0.000361	0.00152	CcSEcCtD
Carfilzomib—Fatigue—Etoposide—urinary bladder cancer	0.000361	0.00152	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.00036	0.00152	CcSEcCtD
Carfilzomib—Pain—Etoposide—urinary bladder cancer	0.000358	0.0015	CcSEcCtD
Carfilzomib—Constipation—Etoposide—urinary bladder cancer	0.000358	0.0015	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—urinary bladder cancer	0.000357	0.0015	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000355	0.00149	CcSEcCtD
Carfilzomib—Asthenia—Gemcitabine—urinary bladder cancer	0.000352	0.00148	CcSEcCtD
Carfilzomib—Nausea—Thiotepa—urinary bladder cancer	0.000346	0.00145	CcSEcCtD
Carfilzomib—ABCB1—lymph node—urinary bladder cancer	0.000346	0.00199	CbGeAlD
Carfilzomib—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000344	0.00145	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—urinary bladder cancer	0.000342	0.00144	CcSEcCtD
Carfilzomib—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000335	0.00141	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—urinary bladder cancer	0.000334	0.00141	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000334	0.0014	CcSEcCtD
Carfilzomib—Body temperature increased—Etoposide—urinary bladder cancer	0.000331	0.00139	CcSEcCtD
Carfilzomib—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00033	0.00139	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000328	0.00138	CcSEcCtD
Carfilzomib—Asthenia—Cisplatin—urinary bladder cancer	0.000328	0.00138	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000327	0.00138	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000325	0.00137	CcSEcCtD
Carfilzomib—Dizziness—Fluorouracil—urinary bladder cancer	0.000319	0.00134	CcSEcCtD
Carfilzomib—Chills—Methotrexate—urinary bladder cancer	0.000316	0.00133	CcSEcCtD
Carfilzomib—Diarrhoea—Cisplatin—urinary bladder cancer	0.000312	0.00131	CcSEcCtD
Carfilzomib—Vomiting—Gemcitabine—urinary bladder cancer	0.000312	0.00131	CcSEcCtD
Carfilzomib—Headache—Gemcitabine—urinary bladder cancer	0.000307	0.00129	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000306	0.00129	CcSEcCtD
Carfilzomib—Vomiting—Fluorouracil—urinary bladder cancer	0.000306	0.00129	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000304	0.00128	CcSEcCtD
Carfilzomib—Headache—Fluorouracil—urinary bladder cancer	0.000302	0.00127	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000301	0.00127	CcSEcCtD
Carfilzomib—Asthenia—Etoposide—urinary bladder cancer	0.0003	0.00126	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—urinary bladder cancer	0.000297	0.00125	CcSEcCtD
Carfilzomib—Chills—Epirubicin—urinary bladder cancer	0.000296	0.00125	CcSEcCtD
Carfilzomib—Nausea—Gemcitabine—urinary bladder cancer	0.000291	0.00122	CcSEcCtD
Carfilzomib—Vomiting—Cisplatin—urinary bladder cancer	0.00029	0.00122	CcSEcCtD
Carfilzomib—Diarrhoea—Etoposide—urinary bladder cancer	0.000286	0.0012	CcSEcCtD
Carfilzomib—Nausea—Fluorouracil—urinary bladder cancer	0.000286	0.0012	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—urinary bladder cancer	0.000284	0.00119	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000283	0.00119	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—urinary bladder cancer	0.000278	0.00117	CcSEcCtD
Carfilzomib—Dizziness—Etoposide—urinary bladder cancer	0.000277	0.00116	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—urinary bladder cancer	0.000276	0.00116	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—urinary bladder cancer	0.000275	0.00116	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—urinary bladder cancer	0.000274	0.00115	CcSEcCtD
Carfilzomib—Nausea—Cisplatin—urinary bladder cancer	0.000271	0.00114	CcSEcCtD
Carfilzomib—Cough—Methotrexate—urinary bladder cancer	0.000268	0.00113	CcSEcCtD
Carfilzomib—Vomiting—Etoposide—urinary bladder cancer	0.000266	0.00112	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—urinary bladder cancer	0.000266	0.00112	CcSEcCtD
Carfilzomib—Headache—Etoposide—urinary bladder cancer	0.000262	0.0011	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—urinary bladder cancer	0.000261	0.0011	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—urinary bladder cancer	0.000257	0.00108	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—urinary bladder cancer	0.000257	0.00108	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000256	0.00107	CcSEcCtD
Carfilzomib—Cough—Epirubicin—urinary bladder cancer	0.000251	0.00105	CcSEcCtD
Carfilzomib—Infection—Methotrexate—urinary bladder cancer	0.000249	0.00105	CcSEcCtD
Carfilzomib—Nausea—Etoposide—urinary bladder cancer	0.000249	0.00105	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—urinary bladder cancer	0.000248	0.00104	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—urinary bladder cancer	0.000246	0.00103	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000245	0.00103	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—urinary bladder cancer	0.000245	0.00103	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—urinary bladder cancer	0.000239	0.001	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—urinary bladder cancer	0.000238	0.001	CcSEcCtD
Carfilzomib—Infection—Epirubicin—urinary bladder cancer	0.000233	0.00098	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—urinary bladder cancer	0.000232	0.000976	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00023	0.000966	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—urinary bladder cancer	0.00023	0.000965	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000228	0.00096	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—urinary bladder cancer	0.000227	0.000953	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—urinary bladder cancer	0.000226	0.000952	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—urinary bladder cancer	0.000224	0.00094	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—urinary bladder cancer	0.000223	0.00094	CcSEcCtD
Carfilzomib—Decreased appetite—Methotrexate—urinary bladder cancer	0.000218	0.000916	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—urinary bladder cancer	0.000216	0.000909	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—urinary bladder cancer	0.000216	0.000907	CcSEcCtD
Carfilzomib—Pain—Methotrexate—urinary bladder cancer	0.000214	0.000901	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000214	0.000898	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000212	0.000893	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—urinary bladder cancer	0.000212	0.000892	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—urinary bladder cancer	0.000209	0.000879	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—urinary bladder cancer	0.000207	0.00087	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—urinary bladder cancer	0.000204	0.000857	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—urinary bladder cancer	0.000202	0.00085	CcSEcCtD
Carfilzomib—Pain—Epirubicin—urinary bladder cancer	0.000201	0.000843	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—urinary bladder cancer	0.000201	0.000843	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—urinary bladder cancer	0.000198	0.000833	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000198	0.000831	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—urinary bladder cancer	0.000196	0.000825	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000193	0.000814	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000189	0.000793	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—urinary bladder cancer	0.000187	0.000787	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—urinary bladder cancer	0.000186	0.00078	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—urinary bladder cancer	0.000186	0.00078	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—urinary bladder cancer	0.000185	0.00078	CcSEcCtD
Carfilzomib—Asthenia—Methotrexate—urinary bladder cancer	0.00018	0.000756	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000172	0.000721	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—urinary bladder cancer	0.000171	0.000721	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—urinary bladder cancer	0.000168	0.000708	CcSEcCtD
Carfilzomib—Dizziness—Methotrexate—urinary bladder cancer	0.000166	0.000697	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—urinary bladder cancer	0.00016	0.000675	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—urinary bladder cancer	0.000159	0.00067	CcSEcCtD
Carfilzomib—Headache—Methotrexate—urinary bladder cancer	0.000157	0.00066	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—urinary bladder cancer	0.000156	0.000655	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—urinary bladder cancer	0.000155	0.000652	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—urinary bladder cancer	0.000149	0.000627	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—urinary bladder cancer	0.000149	0.000626	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000148	0.000624	CcSEcCtD
Carfilzomib—Headache—Epirubicin—urinary bladder cancer	0.000147	0.000618	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—urinary bladder cancer	0.000143	0.000603	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—urinary bladder cancer	0.000139	0.000586	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—urinary bladder cancer	0.000138	0.00058	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—urinary bladder cancer	0.000136	0.000572	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—urinary bladder cancer	0.000129	0.000542	CcSEcCtD
Carfilzomib—PSMB2—Metabolism—PPARG—urinary bladder cancer	2.72e-05	7.4e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—SRC—urinary bladder cancer	2.71e-05	7.39e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PPARG—urinary bladder cancer	2.68e-05	7.3e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—MYC—urinary bladder cancer	2.63e-05	7.16e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—MYC—urinary bladder cancer	2.62e-05	7.13e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—CREBBP—urinary bladder cancer	2.61e-05	7.11e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—CREBBP—urinary bladder cancer	2.61e-05	7.11e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—CREBBP—urinary bladder cancer	2.61e-05	7.11e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—ERBB2—urinary bladder cancer	2.61e-05	7.11e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—ERBB2—urinary bladder cancer	2.61e-05	7.11e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—ERBB2—urinary bladder cancer	2.61e-05	7.11e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—RHOA—urinary bladder cancer	2.61e-05	7.1e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HRAS—urinary bladder cancer	2.6e-05	7.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HRAS—urinary bladder cancer	2.6e-05	7.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HRAS—urinary bladder cancer	2.6e-05	7.07e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—RHOA—urinary bladder cancer	2.6e-05	7.07e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—EGFR—urinary bladder cancer	2.59e-05	7.05e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—CREBBP—urinary bladder cancer	2.58e-05	7.01e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—ERBB2—urinary bladder cancer	2.58e-05	7.01e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—EGFR—urinary bladder cancer	2.58e-05	7.01e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—FGFR3—urinary bladder cancer	2.57e-05	6.99e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—FGFR3—urinary bladder cancer	2.57e-05	6.99e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—FGFR3—urinary bladder cancer	2.57e-05	6.99e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL2—urinary bladder cancer	2.57e-05	6.98e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL2—urinary bladder cancer	2.57e-05	6.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL2—urinary bladder cancer	2.57e-05	6.98e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HRAS—urinary bladder cancer	2.56e-05	6.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTGS2—urinary bladder cancer	2.56e-05	6.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTGS2—urinary bladder cancer	2.56e-05	6.96e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTGS2—urinary bladder cancer	2.56e-05	6.96e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—FGFR3—urinary bladder cancer	2.53e-05	6.89e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL2—urinary bladder cancer	2.53e-05	6.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTGS2—urinary bladder cancer	2.52e-05	6.86e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.5e-05	6.81e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ESR1—urinary bladder cancer	2.49e-05	6.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ESR1—urinary bladder cancer	2.49e-05	6.79e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ESR1—urinary bladder cancer	2.49e-05	6.79e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PTEN—urinary bladder cancer	2.46e-05	6.7e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ESR1—urinary bladder cancer	2.46e-05	6.69e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.45e-05	6.68e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PTEN—urinary bladder cancer	2.45e-05	6.67e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KRAS—urinary bladder cancer	2.45e-05	6.66e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MYC—urinary bladder cancer	2.44e-05	6.65e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—KRAS—urinary bladder cancer	2.43e-05	6.62e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MYC—urinary bladder cancer	2.43e-05	6.62e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CDKN1A—urinary bladder cancer	2.42e-05	6.58e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CDKN1A—urinary bladder cancer	2.42e-05	6.58e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CDKN1A—urinary bladder cancer	2.42e-05	6.58e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—ERBB2—urinary bladder cancer	2.41e-05	6.57e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PTEN—urinary bladder cancer	2.41e-05	6.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PTEN—urinary bladder cancer	2.41e-05	6.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PTEN—urinary bladder cancer	2.41e-05	6.57e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—ERBB2—urinary bladder cancer	2.4e-05	6.54e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.4e-05	6.53e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—EGFR—urinary bladder cancer	2.39e-05	6.51e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CDKN1A—urinary bladder cancer	2.39e-05	6.49e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PTEN—urinary bladder cancer	2.38e-05	6.48e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—EGFR—urinary bladder cancer	2.38e-05	6.47e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—EP300—urinary bladder cancer	2.35e-05	6.39e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—EP300—urinary bladder cancer	2.34e-05	6.36e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EP300—urinary bladder cancer	2.3e-05	6.27e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EP300—urinary bladder cancer	2.3e-05	6.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EP300—urinary bladder cancer	2.3e-05	6.27e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CXCL8—urinary bladder cancer	2.29e-05	6.23e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.29e-05	6.22e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CXCL8—urinary bladder cancer	2.28e-05	6.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EP300—urinary bladder cancer	2.27e-05	6.18e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.27e-05	6.17e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.26e-05	6.15e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KRAS—urinary bladder cancer	2.26e-05	6.15e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KRAS—urinary bladder cancer	2.25e-05	6.12e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—SRC—urinary bladder cancer	2.24e-05	6.09e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—SRC—urinary bladder cancer	2.24e-05	6.09e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—SRC—urinary bladder cancer	2.24e-05	6.09e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CDKN1A—urinary bladder cancer	2.23e-05	6.08e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CDKN1A—urinary bladder cancer	2.23e-05	6.08e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CDKN1A—urinary bladder cancer	2.23e-05	6.08e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTEN—urinary bladder cancer	2.23e-05	6.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTEN—urinary bladder cancer	2.23e-05	6.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTEN—urinary bladder cancer	2.23e-05	6.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—SRC—urinary bladder cancer	2.21e-05	6.01e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CDKN1A—urinary bladder cancer	2.2e-05	5.99e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTEN—urinary bladder cancer	2.2e-05	5.98e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL2—urinary bladder cancer	2.19e-05	5.96e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CREBBP—urinary bladder cancer	2.19e-05	5.95e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CREBBP—urinary bladder cancer	2.19e-05	5.95e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CREBBP—urinary bladder cancer	2.19e-05	5.95e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL2—urinary bladder cancer	2.18e-05	5.93e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IGF1—urinary bladder cancer	2.16e-05	5.87e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IGF1—urinary bladder cancer	2.16e-05	5.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IGF1—urinary bladder cancer	2.16e-05	5.87e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CREBBP—urinary bladder cancer	2.15e-05	5.86e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—urinary bladder cancer	2.14e-05	5.83e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—urinary bladder cancer	2.14e-05	5.83e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—urinary bladder cancer	2.14e-05	5.83e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCND1—urinary bladder cancer	2.13e-05	5.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IGF1—urinary bladder cancer	2.13e-05	5.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EP300—urinary bladder cancer	2.13e-05	5.78e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EP300—urinary bladder cancer	2.13e-05	5.78e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EP300—urinary bladder cancer	2.13e-05	5.78e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCND1—urinary bladder cancer	2.12e-05	5.78e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—urinary bladder cancer	2.11e-05	5.74e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EP300—urinary bladder cancer	2.1e-05	5.7e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—urinary bladder cancer	2.08e-05	5.66e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—urinary bladder cancer	2.07e-05	5.64e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—urinary bladder cancer	2.07e-05	5.63e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—SRC—urinary bladder cancer	2.07e-05	5.63e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—SRC—urinary bladder cancer	2.07e-05	5.63e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—SRC—urinary bladder cancer	2.07e-05	5.63e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CDKN1A—urinary bladder cancer	2.06e-05	5.62e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—urinary bladder cancer	2.06e-05	5.61e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PTEN—urinary bladder cancer	2.06e-05	5.6e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CDKN1A—urinary bladder cancer	2.05e-05	5.59e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PTEN—urinary bladder cancer	2.05e-05	5.58e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—SRC—urinary bladder cancer	2.04e-05	5.55e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.02e-05	5.48e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—urinary bladder cancer	1.99e-05	5.43e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—urinary bladder cancer	1.99e-05	5.43e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—urinary bladder cancer	1.99e-05	5.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—RHOA—urinary bladder cancer	1.98e-05	5.38e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—RHOA—urinary bladder cancer	1.98e-05	5.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—RHOA—urinary bladder cancer	1.98e-05	5.38e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—urinary bladder cancer	1.97e-05	5.35e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EP300—urinary bladder cancer	1.96e-05	5.35e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—urinary bladder cancer	1.96e-05	5.34e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—urinary bladder cancer	1.96e-05	5.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—urinary bladder cancer	1.96e-05	5.34e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EP300—urinary bladder cancer	1.95e-05	5.32e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.95e-05	5.31e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—RHOA—urinary bladder cancer	1.95e-05	5.31e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—urinary bladder cancer	1.93e-05	5.26e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—urinary bladder cancer	1.92e-05	5.22e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—urinary bladder cancer	1.91e-05	5.2e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SRC—urinary bladder cancer	1.91e-05	5.2e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SRC—urinary bladder cancer	1.9e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTEN—urinary bladder cancer	1.87e-05	5.08e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTEN—urinary bladder cancer	1.87e-05	5.08e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTEN—urinary bladder cancer	1.87e-05	5.08e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—urinary bladder cancer	1.85e-05	5.04e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—urinary bladder cancer	1.85e-05	5.04e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—urinary bladder cancer	1.85e-05	5.04e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—urinary bladder cancer	1.85e-05	5.04e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—urinary bladder cancer	1.85e-05	5.04e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—urinary bladder cancer	1.85e-05	5.04e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTEN—urinary bladder cancer	1.84e-05	5.01e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—urinary bladder cancer	1.83e-05	4.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—urinary bladder cancer	1.83e-05	4.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—urinary bladder cancer	1.83e-05	4.98e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—urinary bladder cancer	1.83e-05	4.97e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—urinary bladder cancer	1.83e-05	4.97e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—urinary bladder cancer	1.81e-05	4.93e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—urinary bladder cancer	1.81e-05	4.93e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—urinary bladder cancer	1.81e-05	4.93e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.81e-05	4.92e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.81e-05	4.92e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—urinary bladder cancer	1.8e-05	4.91e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—urinary bladder cancer	1.79e-05	4.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—EP300—urinary bladder cancer	1.78e-05	4.84e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—EP300—urinary bladder cancer	1.78e-05	4.84e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—EP300—urinary bladder cancer	1.78e-05	4.84e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—EP300—urinary bladder cancer	1.75e-05	4.78e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.75e-05	4.77e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—urinary bladder cancer	1.74e-05	4.72e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—urinary bladder cancer	1.74e-05	4.72e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—urinary bladder cancer	1.74e-05	4.72e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—urinary bladder cancer	1.71e-05	4.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—urinary bladder cancer	1.71e-05	4.66e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—urinary bladder cancer	1.71e-05	4.66e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—urinary bladder cancer	1.71e-05	4.66e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—urinary bladder cancer	1.71e-05	4.66e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—urinary bladder cancer	1.7e-05	4.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—urinary bladder cancer	1.69e-05	4.59e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—urinary bladder cancer	1.67e-05	4.56e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—urinary bladder cancer	1.67e-05	4.53e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—urinary bladder cancer	1.66e-05	4.51e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—urinary bladder cancer	1.66e-05	4.51e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—urinary bladder cancer	1.66e-05	4.51e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.64e-05	4.47e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—urinary bladder cancer	1.64e-05	4.45e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—urinary bladder cancer	1.62e-05	4.4e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—urinary bladder cancer	1.62e-05	4.4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—urinary bladder cancer	1.62e-05	4.4e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—urinary bladder cancer	1.59e-05	4.34e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—urinary bladder cancer	1.58e-05	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—urinary bladder cancer	1.58e-05	4.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—urinary bladder cancer	1.58e-05	4.29e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—urinary bladder cancer	1.58e-05	4.29e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—urinary bladder cancer	1.57e-05	4.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—urinary bladder cancer	1.57e-05	4.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—urinary bladder cancer	1.57e-05	4.27e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—urinary bladder cancer	1.57e-05	4.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1A—urinary bladder cancer	1.56e-05	4.26e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.56e-05	4.26e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.56e-05	4.26e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTEN—urinary bladder cancer	1.56e-05	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTEN—urinary bladder cancer	1.56e-05	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTEN—urinary bladder cancer	1.56e-05	4.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—urinary bladder cancer	1.55e-05	4.23e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—urinary bladder cancer	1.55e-05	4.21e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1A—urinary bladder cancer	1.54e-05	4.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTEN—urinary bladder cancer	1.54e-05	4.19e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EP300—urinary bladder cancer	1.49e-05	4.05e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EP300—urinary bladder cancer	1.49e-05	4.05e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EP300—urinary bladder cancer	1.49e-05	4.05e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EP300—urinary bladder cancer	1.47e-05	3.99e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.46e-05	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—urinary bladder cancer	1.45e-05	3.96e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—urinary bladder cancer	1.45e-05	3.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—urinary bladder cancer	1.45e-05	3.96e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SRC—urinary bladder cancer	1.45e-05	3.94e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SRC—urinary bladder cancer	1.45e-05	3.94e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SRC—urinary bladder cancer	1.45e-05	3.94e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—urinary bladder cancer	1.43e-05	3.9e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SRC—urinary bladder cancer	1.43e-05	3.88e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—urinary bladder cancer	1.41e-05	3.83e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—urinary bladder cancer	1.4e-05	3.81e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—urinary bladder cancer	1.34e-05	3.66e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—urinary bladder cancer	1.34e-05	3.64e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—urinary bladder cancer	1.3e-05	3.53e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—urinary bladder cancer	1.3e-05	3.53e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—urinary bladder cancer	1.3e-05	3.53e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—urinary bladder cancer	1.28e-05	3.48e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—urinary bladder cancer	1.27e-05	3.45e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—urinary bladder cancer	1.27e-05	3.45e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—urinary bladder cancer	1.27e-05	3.45e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—urinary bladder cancer	1.25e-05	3.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.22e-05	3.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—urinary bladder cancer	1.2e-05	3.26e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—urinary bladder cancer	1.2e-05	3.26e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—urinary bladder cancer	1.2e-05	3.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—urinary bladder cancer	1.18e-05	3.22e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.13e-05	3.08e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.12e-05	3.04e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.12e-05	3.04e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.07e-05	2.91e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—urinary bladder cancer	1.07e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—urinary bladder cancer	1.07e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—urinary bladder cancer	1.07e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—urinary bladder cancer	1.05e-05	2.86e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.05e-05	2.86e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—urinary bladder cancer	1.02e-05	2.77e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—urinary bladder cancer	1.02e-05	2.77e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—urinary bladder cancer	1.02e-05	2.77e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—urinary bladder cancer	1e-05	2.73e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	9.87e-06	2.69e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—urinary bladder cancer	8e-06	2.18e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.69e-06	2.09e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.3e-06	1.71e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.49e-06	1.49e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—EP300—urinary bladder cancer	5.24e-06	1.43e-05	CbGpPWpGaD
